Eli Lilly And Co (LLY) Shares Sold by Amalgamated Bank

Amalgamated Bank cut its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 3.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 135,427 shares of the company’s stock after selling 4,945 shares during the quarter. Amalgamated Bank’s holdings in Eli Lilly And Co were worth $14,533,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of Eli Lilly And Co during the 2nd quarter worth $114,000. Fort L.P. bought a new position in shares of Eli Lilly And Co during the 2nd quarter worth $121,000. Welch Group LLC bought a new position in shares of Eli Lilly And Co during the 3rd quarter worth $123,000. Zions Bancorporation bought a new position in shares of Eli Lilly And Co during the 3rd quarter worth $128,000. Finally, Mainstay Capital Management LLC ADV grew its stake in shares of Eli Lilly And Co by 98.0% during the 3rd quarter. Mainstay Capital Management LLC ADV now owns 1,218 shares of the company’s stock worth $131,000 after acquiring an additional 603 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 55,590 shares of the firm’s stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $106.41, for a total value of $5,915,331.90. Following the sale, the insider now owns 119,735,214 shares of the company’s stock, valued at approximately $12,741,024,121.74. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Eli & Co Lilly sold 4,500 shares of the firm’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $14.44, for a total value of $64,980.00. Following the completion of the sale, the insider now directly owns 3,915,654 shares in the company, valued at approximately $56,542,043.76. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,962,800 shares of company stock worth $149,601,553. Insiders own 0.11% of the company’s stock.

Several research analysts have recently weighed in on LLY shares. TheStreet downgraded Eli Lilly And Co from a “b” rating to a “c+” rating in a research note on Friday, August 24th. Barclays increased their price target on Eli Lilly And Co from $98.00 to $107.00 and gave the stock an “overweight” rating in a research note on Friday, September 7th. Cantor Fitzgerald set a $110.00 price target on Eli Lilly And Co and gave the stock a “buy” rating in a research note on Monday, September 17th. JPMorgan Chase & Co. set a $117.00 target price on Eli Lilly And Co and gave the stock an “overweight” rating in a research note on Wednesday, September 26th. Finally, Zacks Investment Research downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Friday, September 28th. Nine investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $111.53.

Shares of NYSE LLY opened at $115.84 on Friday. Eli Lilly And Co has a 52 week low of $73.69 and a 52 week high of $119.84. The company has a quick ratio of 1.53, a current ratio of 1.91 and a debt-to-equity ratio of 0.83. The stock has a market capitalization of $123.43 billion, a price-to-earnings ratio of 27.07, a P/E/G ratio of 1.82 and a beta of 0.31.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Tuesday, November 6th. The company reported $1.39 EPS for the quarter, topping the consensus estimate of $1.35 by $0.04. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. The business had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter last year, the company earned $1.05 EPS. The firm’s revenue was up 7.1% compared to the same quarter last year. On average, equities analysts forecast that Eli Lilly And Co will post 5.58 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Shareholders of record on Thursday, November 15th will be issued a $0.5625 dividend. The ex-dividend date is Wednesday, November 14th. This represents a $2.25 annualized dividend and a dividend yield of 1.94%. Eli Lilly And Co’s payout ratio is currently 52.57%.

COPYRIGHT VIOLATION WARNING: “Eli Lilly And Co (LLY) Shares Sold by Amalgamated Bank” was reported by WKRB News and is the property of of WKRB News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.wkrb13.com/2018/12/07/eli-lilly-and-co-lly-shares-sold-by-amalgamated-bank.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Why is Cost of Capital Important?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply